Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48083 | 0.76 | KDM4E (0.44) | KDM4EMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL305332 | 0.71 | KDM4E (0.38) | KDM4EMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL981801 | 0.67 | ABCG2 (0.40) | KDM4EMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL10179796 | 0.67 | CTRC (0.38) | KDM4EMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL5492196 | 0.63 | ADORA3 (0.39) | KDM4EMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL7128881 | 0.63 | PTGS1 (0.43) | KDM4EMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL2468591 | 0.63 | ABCG2 (0.40) | KDM4EMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL2721048 | 0.63 | KDM4E (0.35) | KDM4EMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL22356152 | 0.63 | KDM4E (0.44) | KDM4EMEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL2719464 | 0.63 | TDO2 (0.42) | KDM4EMEN1KMT2ACYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5364869-A | Treatment of hypertension and congestive heart failure | ABBOTT LABORATORIES (US) | 1994-11-15 | — | — | US | claimed |
| EP-0365045-B1 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1993-12-01 | — | — | EP | claimed |
| EP-0161801-B1 | PERHYDROTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANKYO COMPANY LIMITED (JP) | 1990-11-07 | — | — | EP | claimed |
| EP-0365045-A1 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1990-04-25 | — | — | EP | claimed |
| US-4699905-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-13 | — | — | US | claimed |
| EP-0161801-A2 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1985-11-21 | — | — | EP | claimed |
| WO-2024145638-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING TIRZEPATIDE | ELI LILLY AND COMPANY (US) | 2024-07-04 | — | — | WO | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024077149-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | ELI LILLY AND COMPANY (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230303611-A1 | SYNTHESIS OF AN ANTIVIRAL AZASUGAR TRIPHOSPHATE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-09-28 | — | — | US | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-1993017681-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-09-16 | — | — | WO | disclosed |
| WO-1993018035-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-09-16 | — | — | WO | disclosed |
| WO-1993017682-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-09-16 | — | — | WO | disclosed |
| EP-0161801-B1 | PERHYDROTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANKYO COMPANY LIMITED (JP) | 1990-11-07 | — | — | EP | disclosed |
| EP-0365045-A1 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1990-04-25 | — | — | EP | disclosed |
| US-4699905-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-13 | — | — | US | disclosed |
| EP-0161801-A2 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | KDM4E 2409/4885MEN1 4181/4885KMT2A 3355/4885 |
| US-20230303611-A1 | SYNTHESIS OF AN ANTIVIRAL AZASUGAR TRIPHOSPHATE | RNGTT, ADAR, MTAP | KDM4E 1142/4885MEN1 3822/4885KMT2A 1363/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | KDM4E 2044/4885MEN1 4377/4885KMT2A 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.